Structure and function of vascular endothelial growth factor and its receptor system

키워드

참고문헌 (62)

1. Birbrair A, "Pericytes at the intersection between tissue regeneration and pathology", Clin Sci (Lond), 128, pp.81~93 (2015)[DOI]
2. Birbrair A, "Type-2 pericytes participate in normal and tumoral angiogenesis", Am J Physiol Cell Physiol, 307, pp.C25~C38 (2014)[DOI]
3. Alitalo K, "Molecular mechanisms of lymphangiogenesis in health and disease", Cancer Cell, 1, pp.219~227 (2002)[DOI]
4. Davis S, "Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning", Cell, 87, pp.1161~1169 (1996)[DOI]
5. Ferrara N, "The biology of vascular endothelial growth factor", Endocr Rev, 18, pp.4~25 (1997)[DOI]
6. Heldin CH, "Mechanism of action and in vivo role of platelet-derived growth factor", Physiol Rev, 79, pp.1283~1316 (1999)[DOI]
7. Shibuya M, "Structure and function of vascular endothelial growth factor receptor-1 and -2", Curr Top Microbiol Immunol, 237, pp.59~83 (1999)
8. Wang HU, "Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4", Cell, 93, pp.741~753 (1998)[DOI]
9. Smith GA, "Vascular endothelial growth factors: multitasking functionality in metabolism, health and disease", J Inherit Metab Dis, 38, pp.753~763 (2015)[DOI]
10. Carmeliet P, "Molecular mechanisms and clinical applications of angiogenesis", Nature, 473, pp.298~307 (2011)[DOI]
11. Shibuya M, "Vascular endothelial growth factor and its receptor system: physiological functions in angiogenesis and pathological roles in various diseases", J Biochem, 153, pp.13~19 (2013)[DOI]
12. Cross MJ, "VEGF-receptor signal transduction", Trends Biochem Sci, 28, pp.488~494 (2003)[DOI]
13. Harris AL, "Hypoxia--a key regulatory factor in tumour growth", Nat Rev Cancer, 2, pp.38~47 (2002)[DOI]
14. Fontanella C, "Clinical advances in the development of novel VEGFR2 inhibitors", Ann Transl Med, 2, pp.123~ (2014)
15. de Vries C, "The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor", Science, 255, pp.989~991 (1992)[DOI]
16. Terman BI, "Identification of a new endothelial cell growth factor receptor tyrosine kinase", Oncogene, 6, pp.1677~1683 (1991)
17. Shibuya M, "Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis", Exp Cell Res, 312, pp.549~560 (2006)[DOI]
18. Shibuya M, "Involvement of Flt-1 (VEGF receptor-1) in cancer and preeclampsia", Proc Jpn Acad Ser B Phys Biol Sci, 87, pp.167~178 (2011)[DOI]
19. Iyer S, "Structural insights into the binding of vascular endothelial growth factor-B by VEGFR-1(D2): recognition and specificity", J Biol Chem, 285, pp.23779~23789 (2010)[DOI]
20. Davis-Smyth T, "The second immunoglobulin-like domain of the VEGF tyrosine kinase receptor Flt-1 determines ligand binding and may initiate a signal transduction cascade", EMBO J, 15, pp.4919~4927 (1996)
21. Tanaka K, "Characterization of the extracellular domain in vascular endothelial growth factor receptor-1 (Flt-1 tyrosine kinase)", Jpn J Cancer Res, 88, pp.867~876 (1997)[DOI]
22. Waltenberger J, "Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor", J Biol Chem, 269, pp.26988~26995 (1994)
23. Roskoski R Jr, "VEGF receptor protein-tyrosine kinases: structure and regulation", Biochem Biophys Res Commun, 375, pp.287~291 (2008)[DOI]
24. Autiero M, "Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1", Nat Med, 9, pp.936~943 (2003)[DOI]
25. Roskoski R Jr, "Vascular endothelial growth factor (VEGF) signaling in tumor progression", Crit Rev Oncol Hematol, 62, pp.179~213 (2007)[DOI]
26. Brozzo MS, "Thermodynamic and structural description of allosterically regulated VEGFR-2 dimerization", Blood, 119, pp.1781~1788 (2012)[DOI]
27. Leppanen VM, "Structural and mechanistic insights into VEGF receptor 3 ligand binding and activation", Proc Natl Acad Sci U S A, 110, pp.12960~12965 (2013)[DOI]
28. Ruch C, "Structure of a VEGF-VEGF receptor complex determined by electron microscopy", Nat Struct Mol Biol, 14, pp.249~250 (2007)[DOI]
29. Yang Y, "Direct contacts between extracellular membrane-proximal domains are required for VEGF receptor activation and cell signaling", Proc Natl Acad Sci U S A, 107, pp.1906~1911 (2010)[DOI]
30. Markovic-Mueller S, "Structure of the Full-length VEGFR-1 Extracellular Domain in Complex with VEGF-A", Structure, 25, pp.341~352 (2017)[DOI]
31. Christinger HW, "The crystal structure of placental growth factor in complex with domain 2 of vascular endothelial growth factor receptor-1", J Biol Chem, 279, pp.10382~10388 (2004)[DOI]
32. Wiesmann C, "Crystal structure at 1.7 A resolution of VEGF in complex with domain 2 of the Flt-1 receptor", Cell, 91, pp.695~704 (1997)[DOI]
33. McTigue M, "Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors", Proc Natl Acad Sci U S A, 109, pp.18281~18289 (2012)[DOI]
34. McTigue MA, "Crystal structure of the kinase domain of human vascular endothelial growth factor receptor 2: a key enzyme in angiogenesis", Structure, 7, pp.319~330 (1999)[DOI]
35. Okamoto K, "Distinct binding mode of multikinase inhibitor lenvatinib revealed by biochemical characterization", ACS Med Chem Lett, 6, pp.89~94 (2015)[DOI]
36. pyrimidine derivatives: novel VEGFR2 kinase inhibitors binding to inactive kinase conformation, "Bioorg Med Chem", 2010, 7260~7273, 10.1016[DOI]
37. Fong GH, "Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium", Nature, 376, pp.66~70 (1995)[DOI]
38. Hiratsuka S, "Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice", Proc Natl Acad Sci U S A, 95, pp.9349~9354 (1998)[DOI]
39. Landgren E, "Placenta growth factor stimulates MAP kinase and mitogenicity but not phospholipase C-gamma and migration of endothelial cells expressing Flt 1", Oncogene, 16, pp.359~367 (1998)[DOI]
40. Sawano A, "The phosphorylated 1169-tyrosine containing region of flt-1 kinase (VEGFR-1) is a major binding site for PLCgamma", Biochem Biophys Res Commun, 238, pp.487~491 (1997)[DOI]
41. Cunningham SA, "Interaction of the Flt-1 tyrosine kinase receptor with the p85 subunit of phosphatidylinositol 3-kinase. Mapping of a novel site involved in binding", J Biol Chem, 270, pp.20254~20257 (1995)[DOI]
42. Katoh O, "Expression of the vascular endothelial growth factor (VEGF) receptor gene, KDR, in hematopoietic cells and inhibitory effect of VEGF on apoptotic cell death caused by ionizing radiation", Cancer Res, 55, pp.5687~5692 (1995)
43. Shalaby F, "Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice", Nature, 376, pp.62~66 (1995)[DOI]
44. Holmqvist K, "The adaptor protein shb binds to tyrosine 1175 in vascular endothelial growth factor (VEGF) receptor-2 and regulates VEGF-dependent cellular migration", J Biol Chem, 279, pp.22267~22275 (2004)[DOI]
45. Matsumoto T, "VEGF receptor-2 Y951 signaling and a role for the adapter molecule TSAd in tumor angiogenesis", EMBO J, 24, pp.2342~2353 (2005)[DOI]
46. Karkkainen MJ, "Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins", Nat Immunol, 5, pp.74~80 (2004)[DOI]
47. Makinen T, "Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C", D receptor VEGFR-3, 2001, pp.20, 4762~4773
48. Dixelius J, "Ligand-induced vascular endothelial growth factor receptor-3 (VEGFR-3) heterodimerization with VEGFR-2 in primary lymphatic endothelial cells regulates tyrosine phosphorylation sites", J Biol Chem, 278, pp.40973~40979 (2003)[DOI]
49. Hanahan D, "Hallmarks of cancer: the next generation", Cell, 144, pp.646~674 (2011)[DOI]
50. Folkman J, "Tumor angiogenesis: therapeutic implications", N Engl J Med, 285, pp.1182~1186 (1971)[DOI]
51. Carmeliet P, "Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions", Nat Med, 7, pp.575~583 (2001)[DOI]
52. Hattori K, "Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1(+) stem cells from bone-marrow microenvironment", Nat Med, 8, pp.841~849 (2002)[DOI]
53. Maynard SE, "Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia", J Clin Invest, 111, pp.649~658 (2003)[DOI]
54. Irrthum A, "Congenital hereditary lymphedema caused by a mutation that inactivates VEGFR3 tyrosine kinase", Am J Hum Genet, 67, pp.295~301 (2000)[DOI]
55. Rockson SG, "Lymphedema", Am J Med, 110, pp.288~295 (2001)[DOI]
56. Gerber HP, "Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies", Cancer Res, 65, pp.671~680 (2005)
57. Quesada AR, "Anti-angiogenic drugs: from bench to clinical trials", Med Res Rev, 26, pp.483~530 (2006)[DOI]
58. Piao Y, "Targeting intercellular adhesion molecule-1 prolongs survival in mice bearing bevacizumab-resistant glioblastoma", Oncotarget, 8, pp.96970~96983 (2017)
59. Motzer RJ, "Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma", J Clin Oncol, 24, pp.16~24 (2006)[DOI]
60. Chen X, "MAPK, NFkappaB, and VEGF signaling pathways regulate breast cancer liver metastasis", Oncotarget, 8, pp.101452~101460 (2017)
61. Chen Y, "Quantification of STAT3 and VEGF expression for molecular diagnosis of lymph node metastasis in breast cancer", Medicine (Baltimore), 96, pp.e8488~ (2017)[DOI]
62. Schirosi L, "VEGF and TWIST1 in a 16-biomarker immunoprofile useful for prognosis of breast cancer patients", Int J Cancer, 141, pp.1901~1911 (2017)[DOI]

관련 논문AI추천